文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

达格列净通过调节……中的丝裂原活化蛋白激酶信号通路改善肠道干细胞衰老。

Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in .

作者信息

Yan Jinhua, Feng Chenxi, Zhang Hanmei, Luo Ting, Chen Haiyang, Chen Haiou

机构信息

Center of Gerontology and Geriatrics and Laboratory of Metabolism and Aging Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Respiratory Health and Multimorbidity and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.

West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.

出版信息

Front Cell Dev Biol. 2025 Apr 23;13:1576258. doi: 10.3389/fcell.2025.1576258. eCollection 2025.


DOI:10.3389/fcell.2025.1576258
PMID:40337552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12055793/
Abstract

INTRODUCTION: Intestinal stem cells (ISCs) possess the ability to self-renew and differentiate, which is essential for maintaining intestinal tissue homeostasis. However, their functionality significantly declines with age, leading to diminished tissue regeneration and an increased risk of age-associated diseases. METHODS: This study investigates the effects of Dapagliflozin (DAPA), a novel insulin sensitizer and SGLT2 inhibitor, on aging ISCs using the model. Our findings demonstrate that DAPA can inhibit the MAPK signaling pathway, as confirmed by network pharmacology analysis and molecular docking experiments. RESULTS: DAPA ameliorates ISC aging, improves intestinal function (including enhanced fecal excretion, restored intestinal barrier integrity and acid-base balance), and enhances healthspan. These results highlight the potential of DAPA as an anti-aging therapeutic agent. DISCUSSION: This study provides new evidence for the application of DAPA as an anti-aging treatment.

摘要

引言:肠道干细胞(ISC)具有自我更新和分化的能力,这对于维持肠道组织稳态至关重要。然而,它们的功能会随着年龄的增长而显著下降,导致组织再生能力减弱以及与年龄相关疾病的风险增加。 方法:本研究使用该模型研究新型胰岛素增敏剂和钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂达格列净(DAPA)对衰老肠道干细胞的影响。我们的研究结果表明,通过网络药理学分析和分子对接实验证实,达格列净可以抑制丝裂原活化蛋白激酶(MAPK)信号通路。 结果:达格列净改善肠道干细胞衰老,改善肠道功能(包括增强粪便排泄、恢复肠道屏障完整性和酸碱平衡),并延长健康寿命。这些结果凸显了达格列净作为抗衰老治疗药物的潜力。 讨论:本研究为达格列净作为抗衰老治疗的应用提供了新证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8b/12055793/633d9cc5fbce/fcell-13-1576258-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8b/12055793/66c3688a01c4/fcell-13-1576258-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8b/12055793/66cd973f1e5f/fcell-13-1576258-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8b/12055793/37ba6676e03c/fcell-13-1576258-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8b/12055793/633d9cc5fbce/fcell-13-1576258-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8b/12055793/66c3688a01c4/fcell-13-1576258-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8b/12055793/66cd973f1e5f/fcell-13-1576258-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8b/12055793/37ba6676e03c/fcell-13-1576258-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8b/12055793/633d9cc5fbce/fcell-13-1576258-g004.jpg

相似文献

[1]
Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in .

Front Cell Dev Biol. 2025-4-23

[2]
Kaempferol enhances intestinal repair and inhibits the hyperproliferation of aging intestinal stem cells in .

Front Cell Dev Biol. 2024-10-10

[3]
Total ginsenosides extend healthspan of aging Drosophila by suppressing imbalances in intestinal stem cells and microbiota.

Phytomedicine. 2024-7

[4]
Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells.

Cardiovasc Diabetol. 2024-10-29

[5]
Canonical Wnt Signaling Ameliorates Aging of Intestinal Stem Cells.

Cell Rep. 2017-3-14

[6]
Quercetin Prevents Intestinal Stem Cell Aging via Scavenging ROS and Inhibiting Insulin Signaling in .

Antioxidants (Basel). 2022-12-27

[7]
The role of p38b MAPK in age-related modulation of intestinal stem cell proliferation and differentiation in Drosophila.

Aging (Albany NY). 2009-5-21

[8]
Nicotine enhances the stemness and tumorigenicity in intestinal stem cells via Hippo-YAP/TAZ and Notch signal pathway.

Elife. 2025-1-3

[9]
Trametinib ameliorates aging-associated gut pathology in females by reducing Pol III activity in intestinal stem cells.

Proc Natl Acad Sci U S A. 2024-1-23

[10]
Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis MAPK signaling inhibition.

Front Pharmacol. 2023-2-20

本文引用的文献

[1]
Dapagliflozin in Chronic Kidney Disease: Insights from Network Pharmacology and Molecular Docking Simulation.

Life (Basel). 2025-3-11

[2]
Age-related alterations in gut homeostasis are microbiota dependent.

NPJ Biofilms Microbiomes. 2025-3-25

[3]
SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health.

Kidney Med. 2024-6-8

[4]
Mating reconciles fitness and fecundity by switching diet preference in flies.

Nat Commun. 2024-11-15

[5]
Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells.

Cardiovasc Diabetol. 2024-10-29

[6]
Combined dapagliflozin and roxadustat effectively protected heart and kidney against cardiorenal syndrome-induced damage in rodent through activation of cell stress-Nfr2/ARE signalings and stabilizing HIF-1α.

Biomed Pharmacother. 2024-11

[7]
Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy.

BMC Cardiovasc Disord. 2024-7-12

[8]
SGLT2 inhibition eliminates senescent cells and alleviates pathological aging.

Nat Aging. 2024-7

[9]
Intestinal stem cells: guardians of homeostasis in health and aging amid environmental challenges.

Exp Mol Med. 2024-3

[10]
Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.

NEJM Evid. 2024-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索